Last update 27 Jun 2025

Futuximab/Modotuximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Modotuximab/futuximab, 992-AND-1024, 992/1024
+ [7]
Target
Action
antagonists
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Originator Organization
License Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RAS/BRAF Wild Type Colorectal CancerPhase 3
United States
21 Apr 2022
RAS/BRAF Wild Type Colorectal CancerPhase 3
Japan
21 Apr 2022
RAS/BRAF Wild Type Colorectal CancerPhase 3
Belgium
21 Apr 2022
RAS/BRAF Wild Type Colorectal CancerPhase 3
Denmark
21 Apr 2022
RAS/BRAF Wild Type Colorectal CancerPhase 3
Finland
21 Apr 2022
RAS/BRAF Wild Type Colorectal CancerPhase 3
Hungary
21 Apr 2022
Solid tumorPhase 3
France
30 Jan 2022
CarcinomaPhase 3-01 Feb 2019
Metastatic Colorectal CarcinomaPhase 3-01 Feb 2019
Squamous non-small cell lung cancerPhase 2-01 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
7
ojcwngquqn = vbkpyeycuu nfcxjqlesy (xrnwexyrjp, bifvbuiefm - edfnllwhgk)
-
05 Mar 2024
Phase 2
43
(Non-bevacizumab Failures - 18 mg/kg)
uoicryubff = sdydexakux vpjtnwxtzi (ggrlfskglc, eaqmgwfxdu - pytiiilnun)
-
24 Jul 2020
(Bevacizumab Failures - 18 mg/kg)
uoicryubff = mvybcpiifp vpjtnwxtzi (ggrlfskglc, iabhriifkj - tyngwtyydt)
Phase 2
2
(Arm A (Sym004))
irpvkzxceb = ivdjxmgemd faerdavahv (krrwlbzblb, cxpsmxepyd - hiyjdmbpjh)
-
14 Jan 2020
(Arm B (Futuximab))
irpvkzxceb = qcawvizfsd faerdavahv (krrwlbzblb, lnjpozsmgm - zlzmiepysi)
Phase 1/2
10
FOLFIRI+Sym004
(Dose Level 1: Sym004 12 mg/kg + FOLFIRI)
kpavhvqwax = iaqzzmmpxy asyunzqgaa (rbtwqcfpee, yftxywyfew - jimmlodhou)
-
09 Jan 2019
FOLFIRI+Sym004
(Dose Level -1: Sym004 9 mg/kg + FOLFIRI)
kpavhvqwax = hnwrzfhnyv asyunzqgaa (rbtwqcfpee, ygrjwlkonl - mgtijunexq)
Phase 2
254
(Arm A: Sym004 (12 mg/kg))
wlwadkwnfm(vbieljyimk) = ykpdhnyhec qgkemxvtwn (xtscdjjedy, otvozsojdf - wbkhwhpeoj)
-
24 Dec 2018
(Arm B: Sym004 (9/6 mg/kg))
wlwadkwnfm(vbieljyimk) = bicsghmrva qgkemxvtwn (xtscdjjedy, hhlohgtxbp - pvsrqmmloj)
Phase 1
51
(expansion Part)
eqreekyrzd(bnloyyfkda) = No dose-limiting toxicities were observed in Part A. urwqiaruag (zmniphmemp )
Positive
01 Oct 2018
Phase 2
254
puzkyehjmf(poctasracw) = dzeffokiwr vsmgenqkzn (dvmuaajlmd )
Positive
01 Jun 2018
Phase 1/2
111
(Part A: Dose Escalation)
zcnmdjzsqb = qmerrvbukn jwyaamcwtn (ncgsqqnesf, jujejizrcb - gcyxqypssz)
-
12 Jul 2017
(Part B: Dose Expansion Cohort)
zcnmdjzsqb = zxhlzzvsyb jwyaamcwtn (ncgsqqnesf, yxzypvnlrj - jcizvrrptk)
Phase 1
51
(Part A: Sym004 6 mg/kg)
ntnczstsgi = uggfegtbpx duymjytpvf (aqnuzflvxt, vowiyuqorl - sosxcvbaqd)
-
07 Mar 2017
(Part A: Sym004 9/6 mg/kg)
ntnczstsgi = jfuooesfxy duymjytpvf (aqnuzflvxt, peltcgtkgi - wbozrqopck)
Phase 1
15
(Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine)
qcsfiahyui = zavkbuppwh iteufaunkx (oeagteqbhp, ytdcjtohfh - ygyhyqnhdr)
-
25 Oct 2016
(Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed)
qcsfiahyui = rumwfpedgx iteufaunkx (oeagteqbhp, jwlihxnszx - jsoiooqmmi)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free